|
CA2637929A1
(en)
*
|
2006-01-25 |
2007-08-02 |
The Research Foundation Of State University Of New York |
Anti-fcrn antibodies for treatement of auto/allo immune conditions
|
|
US20100166734A1
(en)
*
|
2006-12-20 |
2010-07-01 |
Edward Dolk |
Oral delivery of polypeptides
|
|
WO2009097017A2
(en)
|
2007-09-18 |
2009-08-06 |
The Jackson Laboratory |
Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
|
|
AU2015200004B2
(en)
*
|
2008-04-25 |
2017-02-16 |
Bioverativ Therapeutics Inc. |
Antibodies against fcrn and use thereof
|
|
WO2009131702A2
(en)
*
|
2008-04-25 |
2009-10-29 |
Dyax Corp. |
Antibodies against fcrn and use thereof
|
|
KR101722961B1
(ko)
|
2009-02-11 |
2017-04-04 |
알부메딕스 에이/에스 |
알부민 변이체 및 접합체
|
|
US8232067B2
(en)
|
2009-05-29 |
2012-07-31 |
Brigham & Women's Hospital, Inc. |
Disrupting FCRN-albumin interactions
|
|
EP2493921B1
(en)
|
2009-10-30 |
2018-09-26 |
Albumedix Ltd |
Albumin variants
|
|
EP2556087A1
(en)
|
2010-04-09 |
2013-02-13 |
Novozymes Biopharma DK A/S |
Albumin derivatives and variants
|
|
AU2012262007B2
(en)
|
2011-06-02 |
2017-06-22 |
Takeda Pharmaceutical Company Limited |
Fc receptor binding proteins
|
|
EP2780364A2
(en)
|
2011-11-18 |
2014-09-24 |
Eleven Biotherapeutics, Inc. |
Proteins with improved half-life and other properties
|
|
DK2825556T3
(en)
|
2012-03-16 |
2018-04-16 |
Albumedix As |
albumin Variants
|
|
GB201208370D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Antibodies
|
|
MX2015005363A
(es)
|
2012-11-08 |
2015-11-06 |
Novozymes Biopharma Dk As |
Variantes de albumina.
|
|
AU2014230018B2
(en)
|
2013-03-15 |
2018-02-22 |
Affibody Ab |
New polypeptides
|
|
ZA201506407B
(en)
*
|
2013-03-15 |
2018-11-28 |
Affibody Ab |
New polypeptides
|
|
GB201320066D0
(en)
|
2013-11-13 |
2013-12-25 |
Ucb Pharma Sa |
Biological products
|
|
WO2015081073A2
(en)
*
|
2013-11-26 |
2015-06-04 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for modulating an immune response
|
|
SG11201605203UA
(en)
|
2013-12-24 |
2016-07-28 |
Argen X N V |
Fcrn antagonists and methods of use
|
|
WO2015164605A1
(en)
*
|
2014-04-25 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Compositions and methods for treating subjects with immune-mediated diseases
|
|
AU2015249946A1
(en)
*
|
2014-04-25 |
2016-11-17 |
The Brigham And Women's Hospital Inc. |
Methods to manipulate alpha-fetoprotein (AFP)
|
|
PL3137504T3
(pl)
|
2014-04-30 |
2023-10-16 |
Hanall Biopharma Co., Ltd. |
Przeciwciało wiążące się z FcRn do leczenia chorób autoimmunologicznych
|
|
US10336825B2
(en)
|
2014-04-30 |
2019-07-02 |
Hanall Biopharma Co., Ltd. |
Antibody binding to FcRn for treating autoimmune diseases
|
|
PL3193930T3
(pl)
|
2014-09-17 |
2019-12-31 |
Affibody Ab |
Nowe polipeptydy
|
|
EP3294335B1
(en)
|
2015-05-12 |
2023-07-05 |
Syntimmune Inc. |
Humanized affinity matured anti-fcrn antibodies
|
|
GB201508180D0
(en)
|
2015-05-13 |
2015-06-24 |
Ucb Biopharma Sprl |
Antibodies
|
|
JP7007261B2
(ja)
|
2015-08-20 |
2022-01-24 |
アルブミディクス リミティド |
アルブミン変異体及びコンジュゲート
|
|
CN106957365B
(zh)
*
|
2016-01-11 |
2021-03-16 |
上海交通大学 |
一种单克隆抗体FnAb8及其应用
|
|
GB201618424D0
(en)
*
|
2016-11-01 |
2016-12-14 |
Argenix Bvba |
Treatment of antibody mediated disease
|
|
CA3081144A1
(en)
|
2017-12-08 |
2019-06-13 |
Argenx Bvba |
Use of fcrn antagonists for treatment of generalized myasthenia gravis
|
|
US12202900B2
(en)
|
2018-06-08 |
2025-01-21 |
argenx BV |
Compositions and methods for treating immune thrombocytopenia
|
|
CN113646051A
(zh)
|
2018-10-16 |
2021-11-12 |
Ucb生物制药有限责任公司 |
重症肌无力的治疗方法
|
|
JP7565951B2
(ja)
|
2019-06-07 |
2024-10-11 |
アルジェニクス ビーブイ |
皮下投与に好適なＦｃＲｎインヒビターの医薬製剤
|
|
JP2023509195A
(ja)
|
2020-01-08 |
2023-03-07 |
アルジェニクス ビーブイ |
天疱瘡症を治療する方法
|
|
AU2021292200A1
(en)
*
|
2020-06-17 |
2023-02-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of gene therapy patients
|
|
JP7755725B2
(ja)
*
|
2021-08-13 |
2025-10-16 |
ジャンスー バイオジェッテイ バイオテクノロジー カンパニー リミテッド |
Ｆｃｒｎを特異的に認識する抗体およびその使用
|
|
WO2023198806A1
(en)
*
|
2022-04-13 |
2023-10-19 |
Ose Immunotherapeutics |
New class of molecules for selective clearance of antibody
|
|
AU2023281650A1
(en)
|
2022-05-30 |
2024-10-17 |
Hanall Biopharma Co., Ltd. |
Anti-fcrn antibody or antigen binding fragment thereof with improved stability
|
|
CN119698429A
(zh)
|
2022-06-15 |
2025-03-25 |
阿根思有限公司 |
Fcrn结合分子及使用方法
|